SCHEMBL5534758

SCHEMBL5534758

CC(C)(C)OC(=O)N(CCc1ccc(C(F)(F)F)cc1)C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 3/20 0.60
KCNH2 Q12809 2/20 0.58
SIGMAR1 Q99720 3/20 0.53
UBE2M P61081 2/20 0.48
DCUN1D1 Q96GG9 2/20 0.48
GPR119 Q8TDV5 1/20 0.48
BCHE P06276 1/20 0.48
ACHE P22303 1/20 0.48
BACE1 P56817 1/20 0.48
SLC6A5 Q9Y345 1/20 0.48
HIF1A Q16665 1/20 0.47
EPAS1 Q99814 1/20 0.47
PKM P14618 1/20 0.47
CHRM2 P08172 1/20 0.47
CHRM3 P20309 1/20 0.47
CHRM4 P08173 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28741984 0.82 OPRM1 (0.53) OPRM1KCNH2SIGMAR1ACHEPKM
SCHEMBL20762328 0.81 MEN1 (0.51) OPRM1SIGMAR1
SCHEMBL9884888 0.81 OPRM1 (0.52) OPRM1KCNH2SIGMAR1ACHECHRM2
SCHEMBL5535246 0.80 TACR1 (0.45) DCUN1D1
SCHEMBL20762351 0.80 OPRM1 (0.50) OPRM1SIGMAR1BCHEACHE
SCHEMBL20762603 0.80 MEN1 (0.51) OPRM1SIGMAR1
SCHEMBL12355143 0.80 HSD11B1 (0.47) OPRM1KCNH2SIGMAR1BCHEACHE
SCHEMBL4178459 0.80 CHRM2 (0.51) OPRM1SIGMAR1ACHECHRM2CHRM3
Hydrochloric Acid SCHEMBL8479224 0.80 OPRM1 (0.51) OPRM1SIGMAR1UBE2MDCUN1D1BCHE
SCHEMBL8578092 0.80 HSD11B1 (0.48) OPRM1KCNH2SIGMAR1BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 OPRM1 518/4885KCNH2 3503/4885SIGMAR1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.